Medtronic Expects New Data on Drug-Eluting Stents and Transcatheter Heart Valves to Feature at TCT 2009 Company’s CardioVascular Business
to Showcase Innovative Product Portfolio, Technology Pipeline and
Clinical Research at Annual Meeting of Interventional Cardiologists
September
18, 2009 -- Expecting new data on drug-eluting stents and transcatheter
heart valves to feature prominently at Transcatheter Cardiovascular
Therapeutics (TCT) 2009 next week in San Francisco, Medtronic,
Inc. (NYSE: MDT), today announced plans to showcase its innovative
cardiovascular product portfolio, technology pipeline and clinical
research at the world’s premier annual meeting for interventional
cardiologists.
Three-year results from ENDEAVOR IV (n=1,548) – the large prospective, multicenter 1:1 randomized controlled trial comparing Medtronic’s Endeavor® zotarolimus-eluting coronary stent to Boston Scientific’s Taxus® paclitaxel-eluting coronary stent on the composite safety-and-efficacy endpoint of target vessel failure – will be presented Monday afternoon, at approximately 5:28 pm Pacific time, during The Drug-Eluting Stent Summit Part 1 in Room 104 at San Francisco’s Moscone Center. Principal investigator Dr. Martin B. Leon of New York-Presbyterian Hospital/Columbia University Medical Center and the Cardiovascular Research Foundation will make the presentation.
In addition, three-year results from RESOLUTE (n=129) – the single-arm feasibility study of Medtronic’s next-generation Resolute® zotarolimus-eluting coronary stent – will be released on Monday morning, at approximately 8:00 am Pacific time, at the TCT Web site, www.tctconference.com.
TCT 2009 also features a series of posters and presentations on Medtronic’s unique transcatheter valve (TCV) portfolio, which include the Melody® transcatheter pulmonary valve and the CoreValve® and Ventor® transcatheter aortic valves. Medtronic is committed to leading the development of transcatheter valves for all four positions of the heart: aortic, mitral, pulmonic and tricuspid.
The Melody and CoreValve TCVs are approved for use in clinical practice only outside the United States; the Ventor system is an investigational device worldwide. All three TCVs are investigational in the United States. The U.S. clinical study of the CoreValve TCV is expected to start in mid-2010, pending Investigational Device Exemption (IDE) approval by the FDA. The international feasibility study of the Ventor TCV is expected to complete enrollment by the end of 2009.
Medtronic offers a variety of coronary stents to address the spectrum of clinical need for patients with coronary artery disease. The Endeavor and Resolute stents share the same advanced cobalt alloy platform and cytostatic antiproliferative drug. They also both feature highly biocompatible polymers that contribute to their distinct long-term safety and durable efficacy profiles.
The Endeavor stent is approved for use in clinical practice worldwide. The Resolute stent is approved for use in clinical practice only outside the United States; the U.S. IDE clinical study of the Resolute stent, RESOLUTE US (n=1,399), is underway and expected to complete enrollment by the end of 2009.
Starting Wednesday, when the TCT exhibit hall opens at the Moscone Center, Medtronic staff will showcase the full breadth and depth of the company’s cardiovascular innovations at booth 1911.
Medtronic CardioVascular is committed to advancing the treatment of coronary, peripheral, aortic and structural heart disease through collaboration with leading clinicians, researchers and scientists worldwide.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis,
is the global
leader in medical technology – alleviating pain, restoring health and extending
life for millions of people around the world.
Any forward-looking statements are
subject to risks and uncertainties such as those described in Medtronic’s
Annual Report on Form 10-K for the year ended April 24, 2009. Actual
results may differ materially from anticipated results.
(Disclaimer: external
links to news, press releases and other timely information
sources are provided as a service by Angioplasty.Org, which
is not responsible for the content found on any external
sites. Items marked with a ($$) indicate that the external
site normally restricts viewing to paid subscribers. Other
sites may require free registration.
